Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial

Bulluck, Heerajnarain, Fröhlich, Georg M., Nicholas, Jennifer M., Mohdnazri, Shah, Gamma, Reto, Davies, John, Sirker, Alex, Mathur, Anthony, Blackman, Daniel, Garg, Pankaj, Moon, James C., Greenwood, John P. and Hausenloy, Derek J. (2019) Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial. American Heart Journal, 211. pp. 60-67. ISSN 0002-8703

[img] PDF (Published_Version) - Published Version
Available under License Creative Commons Attribution.

Download (558kB)

Abstract

Mineralocorticoid receptor antagonist (MRA) therapy has been shown to prevent adverse left ventricular (LV) remodeling in ST-segment elevation myocardial infarction (STEMI) patients with heart failure. Whether initiating MRA therapy prior to primary percutaneous coronary intervention (PPCI) accrues additional benefit of reducing myocardial infarct size and preventing adverse LV remodeling is not known. We aimed to investigate whether MRA therapy initiated prior to reperfusion reduces myocardial infarct (MI) size and prevents adverse LV remodeling in STEMI patients.

Item Type: Article
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 18 Nov 2021 01:58
Last Modified: 02 Dec 2021 02:49
URI: https://ueaeprints.uea.ac.uk/id/eprint/82196
DOI: 10.1016/j.ahj.2019.02.005

Actions (login required)

View Item View Item